BUSINESS

Sawai Further Delays Manufacturing Start at Trust Pharmatech Unit

January 11, 2024

Saiwai Group Holdings said on January 10 that it will further push back the resumption of manufacturing operations at its subsidiary Trust Pharmatech scheduled for this week as repair work after the earthquake is taking longer than expected.

The central Japan tremblor caused cracks in some of the buildings at Trust’s three plants in Fukui Prefecture. Although the company was originally planning to bring the sites back online for this year on January 4, it previously told Jiho that it was pushing back the date to sometime in the week of January 9 due to inspections. On January 10, Sawai said that the date will be further delayed to sometime in the week of January 15.

The recovery work for water supply/drainage systems as well as air conditions at the quake-damaged buildings is taking longer than initially expected, said the generic giant. However, there will be no drug supply issues related to this delay as there are enough products in inventory, it said.

Trust manufacturers allopurinol 100 mg tablet products and takes on some processes for esomeprazole capsules 20 mg.

Related Article

BUSINESS

By Philip Carrigan

Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…

By Takashi Ebisawa

Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…